Vivani Medical, Inc.

Vivani Medical is developing NeuroPace-style miniature implantable drug delivery systems, including glucose-responsive insulin implants for diabetes (GP-2). Its 100-point trial score includes 8 Phase 2 and 22 Phase 3 studies — a substantial Phase 3 commitment. Insider buying at 126 transactions is active. The programmable implantable drug delivery approach addresses the compliance and pharmacokinetic limitations of injectable biologics — a platform with broad applicability if the diabetes implant succeeds.

<article class="bts-verified-summary" data-ticker="VANI">
<p>Vivani Medical, Inc. Common Stock (DE) (VANI) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>VANI has 1 Form 4 insider filing recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001266806 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22VANI%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>